Targeted Oncology reviews trending news online for the week of October 9, 2020, including updates in oncology and new information regarding COVID-19.
This week, the FDA granted an Orphan Drug designation in gastric/gastroesophageal junction adenocarcinoma to an investigational chimeric antigen receptor (CAR) T-cell therapy. The FDA also issued a draft guidance encouraging the inclusion of premenopausal women with breast cancer in clinical trials, in order to help researchers determine the efficacy of a hormonal drug or biological products for this population along with others.
Check out the latest conference coverage this weekend from the NCCN 2020 Virtual Congress: Hematologic Malignancies.
The FDA has granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms.
During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.
Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
Topline results from the phase 2 CodeBreaK 100 clinical trial were consistent with phase 1 data, withthe KRAS inhibitor sotorasib (AMG 510) having achieved a satisfactory objective response rate when administered as treatment of patients with KRAS G12C–mutant non–small cell lung cancer, who had failed a median of 2 prior lines of anti-cancer therapies.
In an interview with Targeted Oncology, David J. Pinato, MD, PhD, reviewed how the treatment landscape of hepatocellular carcinoma has evolved over the years and the challenges that clinicians and researchers currently face in the field.
Lori A. Leslie, MD, discusses the approval of tazemetostat in the follicular lymphoma setting and the data that that led to its FDA approval.
In patients with advanced hepatocellular carcinoma treated in 2020, there was an observed decrease in planned treatment as well as significant delays noted as a result of the COVID-19 pandemic, according to the results of a study of 6 academic referral centers.